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Abstract. Gene expression analysis of colon biopsies using high-density oligonucleotide microarrays can contribute to the un-
derstanding of local pathophysiological alterations and to functional classification of adenoma (15 samples), colorectal carci-
nomas (CRC) (15) and inflammatory bowel diseases (IBD) (14). Total RNA was extracted, amplified and biotinylated from
frozen colonic biopsies. Genome-wide gene expression profile was evaluated by HGU133plus2 microarrays and verified by
RT-PCR. We applied two independent methods for data normalization and used PAM for feature selection. Leave one-out
stepwise discriminant analysis was performed. Top validated genes included collagenIVα1, lipocalin-2, calumenin, aquaporin-8
genes in CRC; CD44, met proto-oncogene, chemokine ligand-12, ADAM-like decysin-1 and ATP-binding casette-A8 genes in
adenoma; and lipocalin-2, ubiquitin D and IFITM2 genes in IBD. Best differentiating markers between Ulcerative colitis and
Crohn’s disease were cyclin-G2; tripartite motif-containing-31; TNFR shedding aminopeptidase regulator-1 and AMICA. The
discriminant analysis was able to classify the samples in overall 96.2% using 7 discriminatory genes (indoleamine-pyrrole-2,3-
dioxygenase, ectodermal-neural cortex, TIMP3, fucosyltransferase-8, collectin sub-family member 12, carboxypeptidase D, and
transglutaminase-2). Using routine biopsy samples we successfully performed whole genomic microarray analysis to identify
discriminative signatures. Our results provide further insight into the pathophysiological background of colonic diseases. The
results set up data warehouse which can be mined further.
Keywords: Gene expression signature, whole genomic oligonucleotide microarray, colon cancer, adenoma, inflammatory bowel
disease
1. Introduction
Colorectal cancer (CRC) is one of the most frequent
death-causing tumorous diseases in Western countries.
CRC frequently follows various high-risk conditions
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such as adenomatous polyps and inflammatory bowel
disease (IBD). The exact diagnosis of IBD types is still
often difficult by conventional histology. High-density
oligonucleotide microarray analysis gives an opportu-
nity for studying the genetic and gene expression back-
ground, understanding of local pathophysiological al-
terations and for functional classification of diseases.
To date, microarray analyses reported in the litera-
ture were performed predominantly from surgically re-
moved CRC samples [16], while microarray gene ex-
pression profiling of adenomas and IBDs as colorectal
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diseases predisposing to CRC has been studied less.
Besides the publications dealing with the comparison
of gene expression profiles (GEP) of CRC and normal
colonic mucosa [10,21,29], more and more scientific
studies appear to focus on gene expression background
of CRC progression and metastases development [1–4,
22,25,26,42,43], characterization of CRC subtypes ac-
cording to mRNA expression [3,14,44], the correlation
of GEP with clinicopathological parameters [3,5,7,44],
and on the generation of mRNA expression based prog-
nosis [40]. Microarray-based molecular diagnostics of
malignancy in colon adenoma and CRC samples were
described using 10 [1], 9 [25,26] and 4 [29] adeno-
ma samples compared to adenocarcinoma and normal
colonic tissues. Expression microarray analyses of IBD
samples were performed in order to determine global
GEP of mucosal samples from patients with IBD com-
pared to normal controls [23], to identify novel can-
didates for ulcerative colitis (UC) and/or Crohn’s dis-
ease (CD) genetic susceptibility [24,30], to find marker
genes involved in IBD-related carcinogenesis [38], to
compare expression of entire chemokine family within
IBD and normal patients [31], and to examine changes
in GEP in peripheral blood mononuclear cells in IBD
patients [27].
mRNA expression array analysis is usually per-
formed using high volume surgically removed tissues.
In the gastrointestinal tract, biopsy samples are rou-
tinely taken during the endoscopical examination with
minimal intervention. The mRNA expression study
of these samples could allow further insight into the
development of inflammatory, preneoplastic and neo-
plastic diseases, and these biopsy specimens could be
suitable samples for identifying early diagnostic target
molecules. Colonic biopsies were applied previously
for expression array analysis only in several cases [15,
23,30,31], because, even today, array technology needs
significantly more RNA than can be isolated from tiny
biopsy specimens. However, new techniques and com-
mercial kits have recently become available for the re-
liable mRNA amplification without any effect on the
original gene expression pattern [39].
Genome-wide gene expression profiling studies us-
ing microarrays have the potential to improve the di-
agnosis and treatment of human cancers and other dis-
orders. However, recently appeared whole genom-
ic oligonucleotide microarrays representing more than
47000 transcripts have not been used in any type of
gastrointestinal disorders.
In the present study we aimed to find discriminato-
ry genes between the main diagnostic groups and to
develop and test validation assay system and to con-
firm the applicability of biopsy samples for microarray
analysis-based classification. Another purpose of our
work was to search for altered biological pathways for
explanation of the pathomechanism of these colonic
diseases based on whole genomic mRNA microarray
results.
2. Materials and methods
2.1. Patients and samples
After informed consent, biopsy samples were tak-
en from the colon during the endoscopical interven-
tion before treatment, and stored in RNALater Reagent
(Qiagen Inc., US) at −80◦C. Total RNA was extracted
from biopsies of 15 patients with tubulovillous/villous
adenomas, 15 with colorectal adenocarcinoma (all mi-
crosatellite negative), 9 with active ulcerative colitis
(UC), 5 with active Crohn’s colitis (CD) and of 8
healthy normal controls (Table 1). Detailed patient
specification is described in Supplemental Table 1.
2.2. Methods
2.2.1. Microarray analysis
Total RNA was extracted using RNeasy Mini Kit (Qi-
agen, US) according to the manufacturer’s instructions.
Quantity and quality of the isolated RNA were tested
by measuring of the absorbance and agarose gelelec-
trophoresis. Biotinylated cRNA probes were synthe-
sized from 5–8 µg total RNA and fragmented accord-
ing to the Affymetrix description using GeneChip cD-
NA synthesis reagents and sample cleanup module and
Enzo BioArray HighYield RNA Transcript Labeling
Kit (https://www.affymetrix.com/support/downloads/
manuals/expression s2 manual.pdf – first version).
10µg of each fragmented cRNA sample was hybridized
into HGU133 Plus2.0 array (Affymetrix Inc.) at 45 ◦C
for 16 hours. The slides were washed and stained
using Fluidics Station 450 and antibody amplification
staining method according to the manufacturer’s in-
structions. The fluorescent signals were detected by a
GeneChip Scanner 3000.
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Table 1
Patient groups investigated in our study
Group n Male/female Age Taqman available
Adenoma without dysplasia 6 3/3 65.2 ± 15.9 6
Adenoma with dysplasia 9 3/6 73.6 ± 11.6 6
Ulcerative colitis 9 3/6 43.8 ± 15.9 7
Crohn’s disease 5 2/3 25.6 ± 7.6 1
CRC Dukes B 7 3/4 65.3 ± 13.6 6
CRC Dukes C-D 8 4/4 67.5 ± 11.8 4
Normal 8 4/4 50.6 ± 5.97 5
2.2.2. Statistical analysis
Pre-processing and quality control
Quality control analyses were performed accord-
ing to the suggestions of The Tumor Analysis Best
Practices Working Group [37]. Scanned images were
inspected for artifacts, percentage of present calls
(> 25%) and control of the RNA degradation were eval-
uated. Based on the evaluation criteria all biopsy mea-
surements fulfilled the minimal quality requirements.
According to the above recommendations we have ap-
plied two different normalization methods: MAS 5.0,
and RMA [18]. MAS5.0 applies normalization on an
individual chip; it has excellent specificity and good
sensitivity. RMA applies cross-project normalization;
it has good specificity and excellent sensitivity [37].
Further data analysis and -interpretation have been car-
ried out with both of these pre-processing methods in
order to yield the best comparison and normalization
properties across all measurements.
Feature selection and cluster analysis
We have arranged the complete dataset consist-
ing of 52 expression measurements into classes ac-
cording to the histological properties of the samples.
This selection procedure resulted in six new datasets
(CRC/adenoma/IBD vs. normal, CRC DukesB vs. CRC
DukesC-D, non-dysplastic adenoma vs. dyplastic ade-
noma, UC vs. CD), which were treated as autonomous
classification problems. In order to obtain charac-
teristic signal profiles with high predictive power we
have applied the “Prediction Analysis for Microarrays”
(PAM) [35]. PAM uses soft thresholding to produce a
shrunken centroid, which allows the selection of genes
with high predictive potential. In our experimental set-
up the search for a minimum number of genes with
maximum predictive accuracy is not promising as we
could distinguish two different groups with a very short
gene list. Therefore we decided to set the PAM thresh-
old lower for the selection of the top genes and to pick
the top 100 genes for each condition. Due to the nature
of PAM, at lower threshold the resulting gene list will
be longer, but all genes significant at a higher threshold
will be included in any selected set. Finally, the overlap
of the two lists –based on two different normalizations–
was taken for further analysis. The functional classifi-
cation of the most differentially expressed genes were
performed according to the analysis of RMA top 100
genes in each main disease groups compared to normal
controls.
To visualize the discriminative patterns, hierar-
chical clustering was performed using the Gene-
sis software [34]. Annotation was performed using
the Affymetrix Netaffx analysis centre (http://www.
affymetrix.com/analysis/index.affx). The combined
datasets for further analysis are available in the Gene
Expression Omnibus databank (http://www.ncbi.nlm.
nih.gov/geo/), series accession number: GSE4183.
Discriminant analysis
Further data analysis was performed in the SAS v.8.2
(SAS Institute Inc. Cary, NC, USA) program package
and the discriminant analysis in SPSS v.15.0 program
(SPSS Inc., USA). We have performed a stepwise dis-
criminant analysis among the groups by forward selec-
tion of quantitative variables. The set of variables that
make up each class was assumed to be multivariate nor-
mal with a common covariance matrix. Finally we used
the significant discrimination model (Wilks’ Lambda
was significant) and we have fixed the most important
discriminatory genes. At the end of the analysis we
have made the Leave-one-out classification table.
2.2.3. Taqman RT-PCR
TaqMan real-time PCR was used to measure
the expression of 52 selected genes using an Ap-
plied Biosystems Micro Fluidic Card System in 36
samples, where sufficient RNA could be extracted
(Table 1). The measurements were performed us-
ing an ABI PRISM 7900HT Sequence Detection
System as described in the products User Guide
(http://www.appliedbiosystems.com, CA, USA). For
data analysis the SDS 2.2 software was used. The
extracted delta Ct values (which represent the expres-
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sion normalized to the ribosomal 18S expression) were
grouped according to the histological groups. Then the
Student’s t-test was performed to compare the expres-
sion values between groups.
3. Results
3.1. Identification of discriminatory genes among the
main diagnostic groups
CRC cases are characterized by differentially ex-
pressed genes involved in cell proliferation (pleiotro-
phin, insulin-like growth factor binding protein 5,
REG1A, WNT1 inducible signaling pathway protein
1), adhesion (MCAM, collagens, enactin, laminin gam-
ma 1), and transport (such as aquaporin 8, lipocalin
2 and collagen 4 A1). Adenoma cases showed al-
tered gene expression data in transport (like AB-
CA8, TRPM6), adhesion (such as CXCL12, CD44,
ADAM-like decysin 1), metabolism (like carbonic an-
hydrase I) and proliferation (such as MET protoonco-
gene) functional groups. IBD cases are featured by
the gene expression changes of immune regulation
(such as IFITM3, IFITM1 and proteasome subunit, be-
ta type, 9), cell proliferation (REG1A, tryptophanyl-
tRNA synthetase, interferon stimulated gene 20kDa)
and metabolism (like chitinase 3-like 1, carbonic an-
hydrase I, zinc finger protein 91). The top 100
genes for each condition were picked and the over-
laps of the two lists, based on two different normaliza-
tions were determined. Discriminatory genes between
CRC/adenoma/IBD and normal biopsy samples are list-
ed in Table 2, and considered as the disease type spe-
cific mRNA expression markergroups. The list of the
top 100 genes for each analysis setting including com-
plete annotation and the complete microarray dataset
are shown as supplementary information in Supplemen-
tal Table 2. The average within-PAM cross-validation
misclassification error was found to be 7.3%.
To visualize the expression changes, we have clus-
tered the selected top genes of all biopsy samples to
detect similarities across the sample groups (Fig. 1).
The dendrogram of the 52 colonic cases shows the dis-
crimination potential of the selected genes. The tran-
scripts representing the same gene are found to fit into
the same cluster.
3.2. Discriminant analysis of the array results
We were able to classify the samples using 7 dis-
criminatory genes (indoleamine-pyrrole 2,3 dioxyge-
nase, ectodermal-neural cortex, TIMP3, fucosyltrans-
ferase 8, collectin sub-family member 12, carboxypep-
tidase D, and transglutaminase 2 (Fig. 2). 96.2% of
original grouped cases and 94.3 % of cross-validated
grouped cases were correctly classified (Table 3).
3.3. Discrimination of colonic disease subtypes
The subclassifying genes within the main disease
groups were also identified. The metabolic and trans-
port processes (representing genes like DnaJ homolog
subfamily C member 10, coatomer protein complex
subunit beta) mainly differ between CRC subgroups.
In advanced stages of CRC downregulation of apop-
tosis (such as TIA1 cytotoxic granule-associated RNA
binding protein, forkhead box O3A), and immune re-
sponse (like immunoglobulin heavy constant mu, 2’-
5’-oligoadenylate synthetase 2) was observed, while
carbohydrate, fatty acid metabolism (like glutamine-
fructose-6-phosphate transaminase 1, GDP-mannose
4,6-dehydratase, sterol-C4-methyl oxidase-like, lanos-
terol synthase) and energy metabolism related genes
(such as ATPase inhibitory factor 1) showed higher mR-
NA expression levels in parallel with CRC progression.
In adenoma samples upregulation of proliferation (such
as interferon gamma-inducible protein 16, aminopepti-
dase A, tumor protein D52-like 2) and DNA replication
and transcription regulation (like IGF1, nuclear factor-
like 3, zinc finger protein 452) and downregulation of
immune and defense response (such as immunoglobu-
lin heavy constant mu, T cell receptor gamma variable
9, interferon regulatory factor 4 and tryptase alpha)
were found during the development of dysplastic alter-
ations. CD cases are mainly featured by increased ex-
pression of carbohydrate metabolism genes (like galac-
tosidase alpha, fructose-2,6-biphosphatase 4, maltase-
glucoamylase), while certain cell proliferation (such
as septin 10, platelet derived growth factor D, cyclin
G2), apoptosis (such as BCL10, BIRC4, egl nine ho-
molog 3), immune regulation (like decay accelerating
factor, CD24, CEACAM1), transport (like dual oxidase
2, P450 (cytochrome) oxidoreductase and lipocalin
2), and ubiquitin-dependent protein catabolism (such
as tripartite motif-containing 31, ubiquitin-conjugating
enzyme E2, J1, and Ubiquitin specific protease 53)
genes were found to be overexpressed in UC compared
with CD cases. However, the function of many sub-
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Table 2
Genes differentially expressed in CRC/adenoma/IBD compared to normal mucosa (overlap of genes identified using PAM after both RMA and
MAS 5.0 normalizations)
Probe Set ID Gene Name Gene Symbol Gene Ontology Biological Process Fold change
CRC vs
normal
202112 at von Willebrand factor VWF cell adhesion / platelet activation /re-
sponse to wounding
3.61
211980 at collagen, type IV, alpha 1 COL4A1 phosphate transport 5.21
212531 at lipocalin 2 (oncogene 24p3) LCN2 transport 7.97
240157 at — — — −6.30
220724 at hypothetical protein FLJ21511 FLJ21511 — −4.08
220723 s at hypothetical protein FLJ21511 FLJ21511 — −4.07
203065 s at caveolin 1, caveolae protein, 22kDa CAV1 — 2.70
212768 s at olfactomedin 4 OLFM4 — 3.70
223587 s at amnionless homolog (mouse) AMN development −3.91
206784 at aquaporin 8 AQP8 water transport −5.02
215894 at prostaglandin D2 receptor (DP) PTGDR G-protein coupled receptor protein sig-
naling pathway
−3.30
214845 s at calumenin CALU — 3.23
213119 at solute carrier family 36 (proton/amino
acid symporter), member 1
SLC36A1 amino acid transport −2.27
Adenoma
vs normal
204719 at ATP-binding cassette, sub-family A
(ABC1), member 8
ABCA8 transport −12.78
230204 at — — — −4.05
203510 at met proto-oncogene (hepatocyte growth
factor receptor)
MET cell proliferation/ cell surface recep-
tor linked signal transduction / protein
amino acid phosphorylation
3.91
240389 at — — — −13.50
1552296 at vitelliform macular dystrophy 2-like 2 VMD2L2 ion transport −11.34
224412 s at transient receptor potential cation chan-
nel, subfamily M, member 6
TRPM6 cation transport / protein amino acid
phosphorylation
−11.59
209687 at chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1)
CXCL12 G-protein coupled receptor protein sig-
naling pathway / calcium ion homeosta-
sis /cell adhesion / cell-cell signaling
−6.91
212014 x at CD44 antigen (homing function and In-
dian blood group system)
CD44 cell adhesion /cell-cell adhesion / cell-
matrix adhesion
3.87
205523 at hyaluronan and proteoglycan link pro-
tein 1
HAPLN1 cell adhesion −5.04
206134 at ADAM-like, decysin 1 ADAMDEC1 integrin-mediated signaling pathway/
negative regulation of cell adhesion /
proteolysis and peptidolysis
−6.81
209835 x at CD44 antigen (homing function and In-
dian blood group system)
CD44 cell adhesion /cell-cell adhesion /cell-
matrix adhesion
3.74
205950 s at carbonic anhydrase I CA1 one-carbon compound metabolism −9.77
228507 at Phosphodiesterase 3A, cGMP-inhibited PDE3A lipid metabolism /signal transduction −4.36
225275 at EGF-like repeats and discoidin I-like do-
mains 3
EDIL3 cell adhesion / development −4.38
203000 at stathmin-like 2 STMN2 intracellular signaling cascade /neuron
differentiation
−5.17
236300 at Phosphodiesterase 3A, cGMP-inhibited PDE3A lipid metabolism /signal transduction −3.85
220724 at hypothetical protein FLJ21511 FLJ21511 — −5.26
207504 at carbonic anhydrase VII CA7 one-carbon compound metabolism −8.08
204351 at S100 calcium binding protein P S100P — 4.38
229839 at hypothetical protein MGC45780 MGC45780 phosphate transport −5.04
202242 at transmembrane 4 superfamily member 2 TM4SF2 N-linked glycosylation −3.74
235849 at hypothetical protein MGC45780 MGC45780 phosphate transport −4.59
218756 s at hypothetical protein MGC4172 MGC4172 metabolism −3.65
215657 at — — — −7.77




204931 at transcription factor 21 TCF21 mesoderm development /regulation of
transcription, DNA-dependent
−3.20
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Table 2, continued
Probe Set ID Gene Name Gene Symbol Gene Ontology Biological Process Fold change
207003 at guanylate cyclase activator 2A
(guanylin)
GUCA2A signal transduction −7.55
IBD vs
normal
212203 x at interferon induced transmembrane pro-
tein 3 (1-8U)
IFITM3 immune response / response to biotic
stimulus /
3.41
204279 at proteasome (prosome, macropain) sub-
unit, beta type, 9 (large multifunctional
protease 2)
PSMB9 immune response / proteolysis and pep-
tidolysis / ubiquitin-dependent protein
catabolism
3.77
240389 at — — — −7.81
201601 x at interferon induced transmembrane pro-
tein 1 (9–27)
IFITM1 cell surface receptor linked signal trans-
duction/immune response /negative reg-
ulation of cell proliferation
3.32
214022 s at interferon induced transmembrane pro-
tein 1 (9–27)
IFITM1 cell surface receptor linked signal trans-
duction /immune response /negative reg-
ulation of cell proliferation
2.62
201649 at ubiquitin-conjugating enzyme E2L 6 UBE2L6 ubiquitin cycle 3.31
206059 at zinc finger protein 91 (HPF7, HTF10) ZNF91 carbohydrate metabolism / regulation of
transcription, DNA-dependent
−2.22
224412 s at transient receptor potential cation chan-
nel, subfamily M, member 6
TRPM6 cation transport /protein amino acid
phosphorylation
−7.06
213369 at — — — −6.27
212531 at lipocalin 2 (oncogene 24p3) LCN2 transport 10.96
type discriminatory genes has not been identified yet.
Best differentiating markers between UC and CD were
cyclin-G2, tripartite motif-containing-31, TNFR shed-
ding aminopeptidase regulator-1 and AMICA.
The functional classification of most differentially
expressed genes was performed according to the anal-
ysis of RMA top 100 genes in each disease type sub-
groups. The list of the top 100 genes for each analysis
setting including complete annotation and the complete
microarray dataset are shown as supplementary infor-
mation (Supplemental Table 2). Hierarchical cluster
diagrams of the subgroups, based on RMA top 100
differentially expressed genes can be seen on Fig. 3.
3.4. Gene ontology of selected features
The representative gene ontology categories are
shown to Tables 2 and 3. We have also mapped the se-
lected features to chromosomes (Supplemental Fig. 1).
3.5. Taqman validation
Selection criteria for genes were the different expres-
sion in microarray analysis and the availability of vali-
dated TaqMan probes. Ten “literature” genes were also
selected which were described as CRC related genes.
The complete results of the TaqMan measurements are
presented on Supplemental Table 3. Forty six of the
52 measured genes correlated with the results obtained
using Affymetrix microarrays at a significance of p <
0.05. The expression changes of the selected genes are
summarized in Table 4. The mRNA expression levels
of selected discriminatory genes measured by Taqman
RT-PCR are presented on Supplemental Fig. 2. Global
clustering of all samples using the Taqman validated
genes were also performed (Supplemental Fig. 3). Nor-
mal and UC cases belong to two distinct clusters, but
clusters of CRC and adenoma cases are not clearly sep-
arated, demonstrating the expressional heterogeneity of
CRC.
4. Discussion
Gene expression profiling of 52 colonic biopsy sam-
ples was done by whole genomic HGU133 Plus 2.0
microarrays in order to identify disease specific gene
expression markergroups for objective classification.
We aimed to develop diagnostic mRNA expression
patterns for indentification of adenoma and different
staged CRC and of the minimal list of genes which is
suitable for discrimination of different types of IBD.
Examination of adenoma with/without dysplasia, CRC,
IBD and normal samples in parallel can help to find
condition specific gene expression alteration with a
lower risk of unspecificity due to methodical reasons.
Comparative microarray analysis of biopsies from all
of these kinds of colonic diseases has not been report-
ed so far in the scientific literature. Oligonucleotide
whole genomic microarray analyses of biopsy samples
were found to be highly standardized, reproducible and
provided high quality array results regarding the array
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Fig. 1. Combined clustering dendrogram of the top dicriminative transcripts for IBD, adenoma and CRC. The disease samples were grouped,
normalized and compared to normal controls. Samples, not included in the classification of selected disease are shaded. Repeated transcripts are
marked with arrows.
Fig. 2. Discriminant analysis of colonic biopsy specimens. Note the clear separation of the single classification groups based on the discriminatory
genes detailed in the results section. Group 1 = normal, Group 2 = adenoma, Group 3 = colorectal cancer, Group 4 = inflammatory bowel
disease.
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Table 3
Classification resultsb,c
Group Predicted Group Membership Total
1 2 3 4
Original Count 1 8 0 0 0 8
2 0 15 0 0 15
3 0 1 14 0 15
4 0 0 1 14 15
% 1 100.0 0 0 0 100.0
2 0 100.0 0 0 100.0
3 0 6.7 93.3 0 100.0
4 0 0 6.7 93.3 100.0
Cross-validateda Count 1 8 0 0 0 8
2 0 15 0 0 15
3 1 1 13 0 15
4 0 0 1 14 15
% 1 100.0 0 0 0 100.0
2 0 100.0 0 0 100.0
3 6.7 6.7 86.7 0 100.0
4 0 0 6.7 93.3 100.0
aCross validation is done only for those cases in the analysis. In cross validation,
each case is classified by the functions derived from all cases other than that case.
b96.2% of original grouped cases correctly classified.
c94.3% of cross-validated grouped cases correctly classified.
Fig. 3. Discriminating disease subtypes. Hierarchical clustering of genes associated with disease subtype-differenctiation using the top 100
differentially expressed genes obtained after RMA normalization. A. CRC Dukes B vs. CRC Dukes C-D. B. Adenoma without dysplasia vs
adenoma with dysplasia. C. Ulcerative colitis vs Crohn’s disease.
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Table 4
Taqman measurement of 52 genes
Taqman ID Gene Gene name Affymetrix ID Sample groups p value ddCt Fold change in
Symbol microarrays
Hs00153304 m1 CD44 CD44 antigen 212014 x at AD vs normal 1.82E-07 1.903.87
Hs00157859 m1 GUCA2A guanylate cyclase activator 2A 207003 at AD vs normal 0.000411 −4.34 −7.55
CRC vs normal 0.00871 −3.17 −2.33
Hs00171022 m1 CXCL12 chemokine (C-X-C motif) ligand 12 209687 at AD vs normal 0.00305 −2.04 −6.91
CRC vs normal 0.00735 −1.95 −2.32
Hs00179845 m1 MET met proto-oncogene 203510 at AD vs normal 1,41E-06 2.17 3.91
Hs00200350 m1 ABCA8 ATP-binding cassette, sub-family A
(ABC1), member 8
204719 at AD vs normal 0.000610 −3.35 −12.78
UC vs normal 8.07E-05 −2.70 −2.27
Hs00205545 m1 ADAMDEC1 ADAM-like, decysin 1 206134 at AD vs normal 1.16E-05 −3.69 −6.81
CRC vs normal 9.18E-05 −2.74 −2.26
UC vs normal 0.00439 −1.21 −1.27
Hs00214306 m1 TRPM6 transient receptor potential cation
channel, subfamily M, member 6
224412 s at AD vs normal 5.79E-05 −4.73 −11.59
CRC vs normal 0.00827 −3.09 −2.73
UC vs normal 0.000385 −4.63 −3.48
Hs00153408 m1 MYC v-myc myelocytomatosis viral onco-
gene homolog (avian)
202431 s at AD vs normal 5,99E-06 2.35 2.03
Hs00163869 m1 CA2 carbonic anhydrase II 209301 at AD vs normal 0.000494 −3.75 −3.24
CRC vs normal 0.00193 −3.17 −2.14
Hs00171558 m1 TIMP1 tissue inhibitor of metalloproteinase 1 201666 at AD vs normal 3,90E-07 2.58 1.95
CRC vs normal 0.00153 2.74 3.40
UC vs normal 0.000219 2.36 2.03
Hs00236937 m1 CXCL1 chemokine (C-X-C motif) ligand 1 204470 at AD vs normal 1.66E-05 3.55 5.38
CRC vs normal 0.0114 3.84 13.10
UC vs normal 1.11E-05 4.04 4.78
Hs00236966 m1 CXCL2 chemokine (C-X-C motif) ligand 2 209774 x at AD vs normal 1.24E-05 3.98 5.49
CRC vs normal 0.00204 3.70 9.20
UC vs normal 0.000592 3.68 3.94
Hs00266139 m1 CA1 carbonic anhydrase I 205950 s at AD vs normal 0.000930 −6.13 −9.77
Hs00605175 m1 ADH1B alcohol dehydrogenase IB (class I), be-
ta polypeptide
209613 s at AD vs normal 0.00382 −3.49 −4.27
Hs00154124 m1 AQP8 aquaporin 8 206784 at AD vs normal 0.000378 −6.10 −6.20
CRC vs normal 0.0315 −5.33 −5.02
Hs00194353 m1 LCN2 lipocalin 2 212531 at AD vs normal 2.67E-07 6.13 4.85
CRC vs normal 0.000509 4.83 7.97
UC vs normal 2.15E-06 5.06 3.62
Hs00197437 m1 OLFM4 olfactomedin 4 212768 s at AD vs normal 2.57E-07 7.04 4.28
CRC vs normal 0.000179 6.20 3.70
UC vs normal 4.99E-05 5.68
Hs00154230 m1 CALU calumenin 214845 s at CRC vs normal 0.0145 1.60 3.23
Hs00169795 m1 VWF von Willebrand factor 202112 at CRC vs normal 0.551 3.61
UC vs normal 0.000112 2.44 2.75
Hs00229558 m1 AMN amnionless homolog (mouse) 223587 s at CRC vs normal 0.0499 −2.32 −3.91
Hs00235003 m1 PTGDR prostaglandin D2 receptor 215894 at CRC vs normal 0.997 −3 .30
Hs00266237 m1 COL4A1 collagen, type IV, alpha 1 211980 at CRC vs normal 0.0283 3.38 5.21
Hs00156076 m1 BGN biglycan 213905 x at CRC vs normal 0.120 2.24
Hs00169777 m1 PECAM1 platelet/endothelial cell adhesion
molecule
208983 s at CRC vs normal 0.764 1.59
Hs00174103 m1 IL8 interleukin 8 202859 x at CRC vs normal 0.0283 7.21 20.20
UC vs normal 6.80E-06 5.77 4.13
Hs00204187 m1 DUOX2 dual oxidase 2 219727 at AD vs normal 5.77E-06 5.25 6.00
CRC vs normal 0.00363 4.91 9.70
UC vs normal 7.84E-05 6.35 6.43
Hs00160066 m1 PI3 protease inhibitor 3, skin-derived
(SKALP)
203691 at UC vs normal 0.000257 4.26 3.40
Hs00195812 m1 LIPG lipase, endothelial 219181 at UC vs normal 0.000588 1.35 1.82
Hs00197374 m1 UBD ubiquitin D 205890 s at UC vs normal 0.000261 3.20 2.97
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Table 4, continued
Taqman ID Gene Gene name Affymetrix ID Sample groups p value ddCt Fold change in
Symbol microarrays
Hs00829485 sH IFITM2 interferon induced transmembrane pro-
tein 2 (1-8D)
201315 x at UC vs normal 0.00287 1.66 1.65
Hs00171061 m1 CXCL3 chemokine (C-X-C motif) ligand 3 207850 at UC vs normal 7.48E-05 3.58 3.41
Hs00194145 m1 HMGCS2 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2
204607 at UC vs normal 0.0104 −3.15 −2.14
Hs00234579 m1 MMP9 matrix metalloproteinase 9 203936 s at UC vs normal 0.00724 1.85 2.07
Hs00277299 m1 IL1RN interleukin 1 receptor antagonist 212657 s at UC vs normal 1.10E-05 5.30 3.03
Hs00165949 m1 TIMP3 tissue inhibitor of metalloproteinase 3 201150 s at CRC vs normal 0.274 1.50
CRC vs AD 0.000150 1.14 1.49
Hs00234160 m1 SPARC secreted protein, acidic, cysteine-rich
(osteonectin)
200665 s at CRC vs normal 0.617 2.90
CRC vs AD 0.00176 1.36 1.51
Hs00162613 m1 TCF4 transcription factor 4 212386 at CRC vs AD 0.000982 0.86 1.42
Hs00181211 m1 IGFBP3 insulin-like growth factor binding pro-
tein 3
210095 s at CRC vs AD 0.000216 1.56 1.57
Hs00189021 m1 CALD1 caldesmon 1 212077 at CRC vs AD 0.000188 1.24 1.53
Hs00190740 m1 SPARCL1 SPARC-like 1 (mast9, hevin) 200795 at CRC vs AD 0.000165 1.29 1.62
Hs00249930 s1 RBMS1 RNA binding motif, single stranded in-
teracting protein 1
215127 s at CRC vs AD 0.00566 1.52
Hs00255962 m1 TNS tensin 221748 s at CRC vs AD 0.000278 1.15 1.63
Genes from the literature
Hs00153350 m1 BCL2 B-cell CLL/lymphoma 2 203684 s at CRC vs normal 0.33308
Hs00153353 m1 BIRC5 baculoviral IAP repeat-containing 5
(survivin)
202095 s at CRC vs normal 0.02067 1.51 1.36
Hs00170248 m1 THBS2 thrombospondin 2 203083 at CRC vs normal 0.05582
Hs00171257 m1 TGFB1 transforming growth factor, beta 1 203085 s at CRC vs normal 0.47079
Hs00173626 m1 VEGF vascular endothelial growth factor 210513 s at CRC vs normal 0.04743 1.69 1.29
Hs00181385 m1 IGFR1 insulin-like growth factor receptor 1 203627 at CRC vs normal 0.31769
Hs00193306 m1 EGFR epidermal growth factor receptor 1565483 at CRC vs normal 0.53486
Hs00361600 m1 GUCA1B guanylate cyclase activator 1B (retina) 207003 at CRC vs normal 0.73175
Hs00426322 m1 ACHY S-adenosylhomocysteine hydrolase 200903 s at CRC vs normal 0.00581 1.32 1.34
Hs00162669 m1 TERT telomerase reverse transcriptase 207199 at CRC vs normal 0.80232
P value represents the correlation to the microarray data. ddCt represents the expression difference normalized to the ribosomal 18S expression.
The significant differential expression (p < 0.05) is marked with bold.
sensitivity, present percentage and GAPDH 3’/5’ ra-
tio. This type of analysis results in discriminative sig-
natures, and gives an insight into the pathophysiolog-
ical background of colonic diseases, and additionally,
provides a data warehouse which can be further mined
for in-depth pathway analyses. As recently described,
joint analysis is more efficient than replication based
analysis for two-stage genome-wide association stud-
ies [33]. Therefore we used a one-stage genome wide
analysis to identify relevant gene expression signatures.
For a classification problem comparable to our study a
previous estimation suggested a required sample size
of 51 subjects to detect a 2-fold change of expression
level at alpha = 0.001 at the 90th percentile [41].
The main disease groups were individually com-
pared to healthy controls. CRC samples were unequiv-
ocally distinguished according to the expression level
of 13 genes. Six of them were validated by Taqman
RT-PCR. Among the discriminatory genes lipocalin 2
(LCN2), collagen 4 alpha 1 (COL4A1) and aquaporin
8 (AQP8) were mentioned earlier as CRC-associated
genes. LCN2 transport molecule acts as chemotactic
agent and also regulates the matrix metalloproteinase-9
activity. AQP8 water channel protein is a marker for
non-proliferative colonic epithelial cells, but it is not
expressed by adenoma and CRC in protein level. In
correlation with the findings of Fischer et al., lower
AQP8 mRNA level was found in CRC and adenoma
samples in our study also [13].
Adenoma cases were characterized and distin-
guished according to the expression changes of 27 over-
lapping genes. Seven of them (overexpressed CD44
and MET, and underexpressed GUCA2A, CXCL12,
TRPM6, ABCA8, ADAMDEC1) were confirmed by
Taqman RT-PCR. CD44 cell surface glycoprotein anti-
gen is a receptor for hyaluronic acid, which can also
bind osteopontin, EGFR, matrix metalloproteases and
IGFBP3. The expression changes of CD44 can affect
several different cellular pathways including EGFR-
related proliferation and tumorigenesis, tumor tissue
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remodeling and immune processes. Hepatocyte growth
factor receptor (MET), which was found to be overex-
pressed both in colon adenoma and CRC, may play an
important role in colorectal tumorigenesis. Similarly
to the results of Trovato et al., in our study elevated
c-met mRNA level was observed both in adenoma and
CRC biopsies, but CRC samples showed lower c-met
expression than adenomas. Reduced expression of c-
met can be associated to the progression of adenoma
into carcinoma [36]. GUCA2A (guanylin) plays role
in the regulation of ion transport in the colon. Expres-
sion of guanylin is downregulated in human intestinal
adenomas, moreover, recent results suggest that loss of
guanylin activity leads to or is a result of adenocarci-
noma [8]. The chemokine ligand 12 (CXCL12) which
was found underexpressed both in different carcinomas
earlier [32] and adenoma samples in our study, regu-
lates cAMP production and ion transport in intestinal
epithelial cells [12]. These data can support that alter-
ations in ion transport of the colon are involved in col-
orectal carcinogenesis. The exact cellular function and
role in adenoma and tumor development of TRPM6,
ABCA8 and ADAMDEC1 gene products have not yet
been determined.
Several genes were found to show elevated mRNA
level according to the adenoma-CRC sequence. TCF4
is a transcriptional factor involved in Wnt-signalling
pathway which is altered in over 90% of CRCs. TCF4
participates in transcriptional regulation of genes asso-
ciated with colon carcinogenesis including c-myc, cy-
clin D1, TCF1, PPARδ, MMP7 and MDR1. Tensin 1
(TNS1) which was also overexpressed in CRC com-
pared to adenoma samples can also induce JNK and p38
activation leading to increased cell survival. RBMS1 is
an another gene which was detected as being upregu-
lated in CRC compared to adenoma, it is also involved
in the malignant transformation process. RBMS1 is
a modulator of c-myc, deregulates cell cycle controls
and leads cells towards transforming pathways [28].
SPARC (osteonectin) was detected as overexpressed
gene in CRC in several microarray-based studies [10,
29,42]. It is thought to play an important role in tissue
remodeling, angiogenesis, and tumorigenesis. Contro-
versial and conflicting data were published about the
expression and function of insulin-like growth factor
binding protein 3 and SPARCL1 in different types of
cancers including CRC [19,20].
Ten discriminatory transcripts distinguish between
IBD samples and normal tissue. Overexpression of dif-
ferent interferon-induced genes is highly represented
among the discriminatory genes. Interferon induced
transmembrane protein 3 (IFITM3) was strongly ex-
pressed in severely inflamed colonic mucosa of UC
both in our microarray analysis and other studies [17].
Moreover, IFITM3 showed high mRNA level in spo-
radic cancers, and UC-associated cancers, therefore it
can be a marker for identification of high cancer-risk
group within the UC. PSMB9 and UBE2L6 interferon-
induced discriminatory genes are in connection with the
enhanced antigen processing and presentation. LCN2
which has been mentioned above as an upregulated
CRC-associated gene is also overexpressed in colono-
cytes and neutrophils in inflamed lesions of UC. Sim-
ilarly to our findings, highly increased LCN2 mRNA
levels were measured in UC samples in other microar-
ray studies [11,24]. Alteration of epithelial magnesium
absorption was also observed in our IBD samples, as
the TRPM6 (transient receptor potential cation chan-
nel, subfamily member 8) showed lower mRNA lev-
el. CD cases are mainly featured by increased expres-
sion of carbohydrate metabolism genes, while certain
cell proliferation, apoptosis, immune regulation, trans-
port, and ubiquitin-dependentprotein catabolism genes
were found to be overexpressed in UC compared with
CD cases. However, the function of many dicrimi-
natory genes has not been identified yet. Significant
overexpression of cancer-related genes (CEACAM1,
-7, CD24, PDGFD) in UC is potentially important, con-
sidering reports of increased risk of developing CRC in
this disease [6,9].
For validation of the marker properties of a given
gene, we should use homogeneous high case-number
sample groups for microarray analysis, and further ex-
periments, but at least RT-PCR confirmation, are need-
ed. We focused on individual markers and independent
validation of markers. Ninety-four percent of 52 se-
lected genes which were found to be over- or underex-
pressed was confirmed by Taqman RT-PCR.
In conclusion, in our study we were able to distin-
guish not just between normal, adenoma, CRC and IBD
samples, but also among the different stages of CRC
using only easily-taken biopsy specimens. With a large
number of samples one can establish principal gene
lists that characterize distinct conditions, and if miniar-
rays will be commercially available, the daily routine
of diagnosis may be quicker and easier.




Sample Affy ID Sex Age Localization Histology TNM Grade Dukes Dysplasia Taqman
analysis
Adenoma
956* 956 U133 Plus 2.0 .CEL F 84 flexure hepatica adenoma villous severe
983* 983 U133 Plus 2.0 .CEL F 64 rectum adenoma tubulovillous severe Yes (3.)
1115* 1115 U133 Plus 2.0 .CEL F 75 coecum adenoma tubulovillous severe
1141 1141 U133 Plus 2.0 .CEL M 63 rectum adenoma tubulovillous moderate Yes (10.)
1187* 1187 U133 Plus 2.0 .CEL F 80 coecum adenoma tubulovillous moderate Yes (13.)
1312* 1312 U133 Plus 2.0 .CEL M 93 rectum adenoma villous severe Yes (15.)
1700* 1700 U133 Plus 2.0 .CEL F 69 coecum adenoma tubulovillous severe
1748* 1748 U133 Plus 2.0 .CEL F 78 colon desc adenoma villous severe Yes (32.)
1832* 1832 U133 Plus 2.0 .CEL M 56 sigma-colon desc adenoma villous moderate Yes (34.)
980 980 U133 Plus 2.0 .CEL F 83 coecum adenoma tubulovillous no Yes (2.)
995* 995 U133 Plus 2.0 .CEL M 58 coecum, coecum,
rectum
adenoma tubulovillous no Yes (4.)
1138* 1138 U133 Plus 2.0 .CEL M 70 rectum adenoma tubulovillous no Yes (9.)
1154* 1154 U133 Plus 2.0 .CEL F 73 coecum adenoma tubulovillous no Yes (11.)
1419* 1419 U133 Plus 2.0 .CEL F 37 rectum adenoma villous no Yes (19.)
1830* 1830 U133 Plus 2.0 .CEL M 70 sigma adenoma tubulovillous no Yes (33.)
CRC
1158* 1158 U133 Plus 2.0 .CEL M 56 rectum adenocarcinoma T3N0M0 G2 B2 Yes (12.)
1293* 1293 U133 Plus 2.0 .CEL F 88 ascendent colon adenocarcinoma T3N0M0 G3 B2 Yes (14.)
1486* 1486 U133 Plus 2.0 .CEL F 51 hepatic flexure adenocarcinoma T2N0M0 G1 B1 Yes (23.)
1708* 1708 U133 Plus 2.0 .CEL F 72 sigma adenocarcinoma T3N0M0 G2 B2 Yes (30.)
1739* 1739 U133 Plus 2.0 .CEL F 76 colon desc adenocarcinoma T4N0M0 G1 B3 Yes (31.)
1761 1761 U133 Plus 2.0 .CEL M 58 rectum adenocarcinoma T2N0M0 G2 B1
1883* 1883 U133 Plus 2.0 .CEL M 56 coecum tumor adenocarcinoma T3N0M0 G2 B2 Yes (35.)
1146* 1146 U133 Plus 2.0 .CEL M 46 descendent colon adenocarcinoma T2N1M0 G2 C1
1316* 1316 U133 Plus 2.0 .CEL M 85 lienic flexure adenocarcinoma T3N1M1 G2 D Yes (16.)
1377* 1377 U133 Plus 2.0 .CEL F 69 sigma adenocarcinoma T4N1M0 G1-2 C3
1479* 1479 U133 Plus 2.0 .CEL F 77 sigma adenocarcinoma T4NOM1 G1 D
1494* 1494 U133 Plus 2.0 .CEL M 73 rectum adenocarcinoma T3N1M1 G1 D Yes (24.)
1499* 1499 U133 Plus 2.0 .CEL M 65 rectum adenocarcinoma T3N0M1 G1 D
1556* 1556 U133 Plus 2.0 .CEL F 66 coecum adenocarcinoma T3N1M1 G2 D Yes (26.)
1651 1651 U133 Plus 2.0 .CEL F 59 rectum adenocarcinoma T2N0M1 G1 D Yes (28.)
IBD
939 939 U133 Plus 2.0 .CEL F 34 sigma,rectum severe active ulcerative
colitis
no Yes (1.)
1017 1017 U133 Plus 2.0 .CEL F 39 total colon severe active ulcerative
pancolitis
no Yes (5.)
1060 1060 U133 Plus 2.0 .CEL F 73 total colon severe active ulcerative
colitis
no Yes (7.)
1156 1156 U133 Plus 2.0 .CEL M 45 sigma,rectum severe active ulcerative
colitis
no
1175 1175 U133 Plus 2.0 .CEL M 43 total colon severe active ulcerative
colitis
no
1368 1368 U133 Plus 2.0 .CEL F 24 total colon severe active ulcerative
colitis
mild Yes (18.)
1533 1533 U133 Plus 2.0 .CEL F 35 rectum,sigma severe active ulcerative
colitis
no Yes (25.)
1606 1606 U133 Plus 2.0 .CEL F 35 total colon severe active ulcerative
pancolitis
no Yes (27.)
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Supplement Table 1, continued
Sample Affy ID Sex Age Localization Histology TNM Grade Dukes Dysplasia Taqman
analysis
923 923 U133 Plus 2.0 .CEL F 37 sigma,rectum severe active Crohn’s
disease
no
1110 1110 U133 Plus 2.0 .CEL F 16 total colon severe active Crohn’s
disease
mild Yes (8.)
1118 1118 U133 Plus 2.0 .CEL M 26 right side severe active Crohn’s
disease
no
1670 1670 U133 Plus 2.0 .CEL M 23 total colon severe active Crohn’s
disease
no




1024 1024 U133 Plus 2.0 .CEL F 47 normal Yes (6.)
1081 1081 U133 Plus 2.0 .CEL F 57 normal
1114 1114 U133 Plus 2.0 .CEL F 60 normal
1122 1122 U133 Plus 2.0 .CEL M 45 normal
1357 1357 U133 Plus 2.0 .CEL M 47 normal Yes (17.)
1431 1431 U133 Plus 2.0 .CEL M 50 normal Yes (20.)
1440 1440 U133 Plus 2.0 .CEL F 44 normal Yes (21.)
1456 1456 U133 Plus 2.0 .CEL M 55 normal Yes (22.)
Microsatellite instability analysis was done from samples marked with *.
GEO Accession numbers: “normal: GSM95473 – GSM95480”, “adenoma: GSM95481 – GSM95495”, “CRC: GSM95496 – GSM95510”,
“IBD: GSM95511 – GSM95525”.
Supplement Figure 1. Chromosomal localization of discriminatory genes.
The Supplemental Table 2 and the Supplemental Table 3 are available on the http://3dhistech.com/en/article/
DMA-511 website.
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Supplement Figure 2. mRNA expression levels of selected discriminatory genes measured by Taqman RT-PCR. dCt is the expression value
normalized to the ribosomal 18S protein.
Supplement Figure 3. Global clustering of all samples measured by Taqman RT-PCR according to the Taqman validated genes. Probably due the
heterogeneity of CRC samples they do not cluster together during global clustering using Taqman-generated results.
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